Prolonged Heterogeneous Liver Enhancement on Contrast-Enhanced Ultrasound

X. W. Cui; A. Ignee; M. Hocke; K. Seitz; G. Schrade; C. F. Dietrich

doi:10.1055/s-0033-1350202

Ultraschall in der Medizin - European Journal of Ultrasound, Inhaltsverzeichnis

Ultraschall Med 2014; 35(3): 246-252
DOI: 10.1055/s-0033-1350202

Original Article

Prolonged Heterogeneous Liver Enhancement on Contrast-Enhanced Ultrasound

Andauernde heterogene Kontrastmittelanreicherung der Leber

X. W. Cui

¹Medical department 2, Caritas-Krankenhaus, Academic Teaching Hospital of the University of Würzburg, Bad Mergentheim

,

A. Ignee

¹Medical department 2, Caritas-Krankenhaus, Academic Teaching Hospital of the University of Würzburg, Bad Mergentheim

,

M. Hocke

²Medical department 2, Hospital Meiningen GmbH, Academic Teaching Hospital of the University of Jena, Meiningen

,

K. Seitz

³Medizinische Klinik, Ultraschall, Kreiskrankenhaus Sigmaringen

,

G. Schrade

⁴Medical department, Klinikum Westallgäu, Hospital Wangen

,

C. F. Dietrich

¹Medical department 2, Caritas-Krankenhaus, Academic Teaching Hospital of the University of Würzburg, Bad Mergentheim

› Institutsangaben

Abstract

Introduction: Prolonged heterogeneous liver enhancement (PHLE) is a rare phenomenon that is similar to the ultrasound findings of portal venous gas. The purpose of this report is to describe the phenomenon of PHLE after the injection of the ultrasound contrast agent SonoVue^®.

Patients and Methods: From 2000 to 2013, 13 patients with PHLE (“cloudy”, “wool-like”) after bolus injection of SonoVue^® were observed. The height, weight, and body mass index (BMI) of the patients, and the number of injections were analyzed. In addition, the literature was reviewed.

Results: The phenomenon occurred as early as 2 minutes after bolus contrast administration and lasted up to 5 hours on both B-mode and contrast-specific ultrasound. 8/13 (62 %) patients received two or more boluses. None of the patients experienced SonoVue^®-related side effects or health problems. The phenomenon was not reproducible in 3 patients who received a second SonoVue^® injection 24 hours after receiving the first.

Conclusion: This phenomenon is more likely to occur in patients who receive high-dose (or multiple) injections of UCA. It may occur as early as 2 minutes after contrast administration, and therefore, may affect the evaluation of focal liver lesions in the late phase. This phenomenon should not be misdiagnosed as a pathological finding of the liver.

Zusammenfassung

Einleitung: Die langanhaltende heterogene Leberanreicherung (PHLE) entspricht einem seltenen Phänomen portalvenöser Gaseinlagerung durch Kontrastmittelsonografie. Die vorliegende Studie beschreibt das Phänomen nach Injektion des Ultraschallkontrastmittels SonoVue^® und diskutiert mögliche zugrundeliegende Hypothesen.

Patienten und Methode: Von 2000 bis 2013 wurden 13 Patienten mit einer heterogenen (wolkigen) Leberanreicherung nach Bolusinjektion von SonoVue^® beobachtet. Die Größe, das Gewicht und der Body Mass Index (BMI) der Patienten und die Anzahl der Injektionen wurden erfasst. Zusätzlich wurde eine Literaturrecherche zum Thema durchgeführt.

Ergebnis: Das Phänomen wurde frühestens zirka 2 Minuten nach Kontrastmittelinjektion beobachtet und war bis zu 5 Stunden im B-Bild und kontrastspezifischer Einstellung nachweisbar. Das Phänomen wurde gehäuft (aber nicht ausschließlich) bei jungen untergewichtigen Frauen beobachtet. 8 von 13 Patienten (62 %) erhielten 2 und mehr Kontrastmittelinjektionen. Keiner der beobachteten Patienten zeigte Nebenwirkungen oder gesundheitliche Probleme. Das Phänomen konnte bei 3 von 13 Patienten nicht reproduziert werden.

Zusammenfassung: Das an sich harmlose Phänomen kann gehäuft bei jungen untergewichtigen Frauen nach mehrfacher Kontrastinjektion beobachtet werden. Es entwickelt sich nach ca. 2 Minuten und kann somit die Beurteilung der späteren Kontrastphasen beeinflussen und sollte nicht als Leberpathologie fehl diagnostiziert werden.

Key words

ultrasound - microbubbles - liver - heterogeneous enhancement

Volltext

Referenzen

References
1 Claudon M, Dietrich CF, Choi BI et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34: 11-29
2 Lim AK, Patel N, Eckersley RJ et al. Evidence for spleen-specific uptake of a microbubble contrast agent: a quantitative study in healthy volunteers. Radiology 2004; 231: 785-788
3 Metzler B, Blank W, Horn H et al. Gas in the portal vein system of the liver. Value of ultrasound. Z Gastroenterol 1993; 31: 617-620
4 Strohm WD, Rommele UE. The value of ultrasound in detection of collected gas in the portal vein or hepatic veins. Med Klin (Munich) 1994; 89: 538-542
5 Okada M, Albrecht T, Blomley MJ et al. Heterogeneous delayed enhancement of the liver after ultrasound contrast agent injection--a normal variant. Ultrasound Med Biol 2002; 28: 1089-1092
6 Caruso G, Martegani A, Aiani L et al. Heterogeneous delayed enhancement of hepatic parenchyma after intravenous infusion of sonographic contrast agent: a new hypothesis. Radiol Med 2007; 112: 56-63
7 Dietrich CF, Weiper D, Brunner V et al. Echogen-Emulsion: Erste Erfahrungen mit einem neuen Signalverstaerker bei der Untersuchung der Leber. Ultraschall in Med 1998; 19: S21 (Abstract)
8 Dietrich CF, Ignee A, Trojan J et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004; 53: 401-405
9 Bernatik T, Seitz K, Blank W et al. Unclear focal liver lesions in contrast-enhanced ultrasonography--lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall in Med 2010; 31: 577-581
10 Strobel D, Bernatik T, Blank W et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (</= 20 mm) and subcentimetric (</= 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial.. Ultraschall in Med 2011; 32: 593-597
11 Dietrich CF, Kratzer W, Strobe D et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12: 1699-1705
12 Dietrich CF, Maddalena ME, Cui XW et al. Liver tumor characterization--review of the literature. Ultraschall in Med 2012; 33 (Suppl. 01) S3-10
13 Dietrich CF, Cui XW, Schreiber-Dietrich DG et al. EFSUMB guidelines 2011: comments and illustrations. Ultraschall in Med 2012; 33 (Suppl. 01) S11-S21
14 Dietrich CF, Jenssen C. Focal liver lesion, incidental finding. Dtsch Med Wochenschr 2012; 137: 2099-2116
15 Dietrich CF, Schuessler G, Trojan J et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78 (932) 704-707
16 Hocke M, Ignee A, Topalidis T et al. Contrast-enhanced endosonographic Doppler spectrum analysis is helpful in discrimination between focal chronic pancreatitis and pancreatic cancer. Pancreas 2007; 35: 286-288
17 Hocke M, Schulze E, Gottschalk P et al. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J Gastroenterol 2006; 12: 246-250
18 von Herbay A, Barreiros AP, Ignee A et al. Contrast-enhanced ultrasonography with SonoVue: differentiation between benign and malignant lesions of the spleen. J Ultrasound Med 2009; 28: 421-434
19 Ignee A, Straub B, Brix D et al. The value of contrast enhanced ultrasound (CEUS) in the characterisation of patients with renal masses. Clin Hemorheol Microcirc 2010; 46: 275-290
20 Ignee A, Straub B, Schuessler G et al. Contrast enhanced ultrasound of renal masses. World J Radiol 2010; 2: 15-32
21 Dietrich CF, Ignee A, Barreiros AP et al. Contrast-enhanced ultrasound for imaging of adrenal masses. Ultraschall in Med 2010; 31: 163-168
22 Dietrich CF. 3D real time contrast enhanced ultrasonography, a new technique. Rofo 2002; 174: 160-163
23 Dietrich CF, Ignee A, Frey H. Contrast-enhanced endoscopic ultrasound with low mechanical index: a new technique. Z Gastroenterol 2005; 43: 1219-1223
24 Heineck G. Height and weight in Germany, evidence from the German Socio-Economic Panel, 2002. Econ Hum Biol 2006; 4: 359-382
25 Hiermeyer M. Height and BMI values of German conscripts in 2000, 2001 and 1906. Econ Hum Biol 2009; 7: 366-375
26 Dietrich CF, Cui XW, Barreiros AP et al. EFSUMB guidelines 2011: comment on emergent indications and visions. Ultraschall in Med 2012; 33: S39-S47
27 Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153-1166
28 Rasmussen H, Dirven HA, Grant D et al. Etiology of cecal and hepatic lesions in mice after administration of gas-carrier contrast agents used in ultrasound imaging. Toxicol Appl Pharmacol 2003; 188: 176-184
29 Abboud B, El Hachem J, Yazbeck T et al. Hepatic portal venous gas: physiopathology, etiology, prognosis and treatment. World J Gastroenterol 2009; 15: 3585-3590
30 Schuessler G, Ignee A, Hirche T et al. Improved detection and characterisation of liver tumors with echo-enhanced ultrasound. Z Gastroenterol 2003; 41: 1167-1176
31 Strohm WD, Rommele UE. The value of ultrasound in detection of collected gas in the portal vein or hepatic veins. Med Klin (Munich) 1994; 89: 538-542
32 Metzler B, Blank W, Horn H et al. Gas in the portal vein system of the liver. Value of ultrasound. Z Gastroenterol 1993; 31: 617-620
33 Schuessler G, Ignee A, Hirche T et al. Improved detection and characterisation of liver tumors with echo-enhanced ultrasound. Z Gastroenterol 2003; 41: 1167-1176
34 Metzler B, Blank W, Horn H et al. Gas in the portal vein system of the liver. Value of ultrasound. Z Gastroenterol 1993; 31: 617-620
35 Pan HB, Huang JS, Yang TL et al. Hepatic portal venous gas in ultrasonogram--benign or noxious. Ultrasound Med Biol 2007; 33: 1179-1183